Novanta Reports Significant Revenue Growth in 2025 Financial Results

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: Feb 23 2026

0mins

NOVT-1.81%

Should l Buy NOVT?

Source: Businesswire

Strong Financial Performance: Novanta achieved GAAP revenue of $258.3 million in Q4 2025, reflecting an 8.5% year-over-year increase, primarily driven by acquisition-related revenue growth and favorable foreign exchange impacts, showcasing the company's robust growth potential in the medical and advanced technology equipment sectors.
Improved Profitability Metrics: Adjusted EBITDA rose 17% to $60.7 million in Q4, with adjusted EPS increasing 20% to $0.91, indicating successful operational efficiency and cost control measures that enhance confidence in future profitability.
Robust Customer Orders: Customer bookings surged 25% in Q4 2025, with a book-to-bill ratio of 1.11, demonstrating strong market demand and laying a solid foundation for continued growth into 2026.
Optimistic Future Outlook: The company anticipates GAAP revenue for 2026 to range between $1.03 billion and $1.05 billion, with adjusted EBITDA expected between $245 million and $250 million, reflecting confidence in new product launches and market execution aimed at enhancing shareholder value through acquisitions.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NOVT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on NOVT

About NOVT

Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Novanta CEO Matthijs Glastra Sells 7,500 Shares for $1.09 Million

5 days agoFool

Transaction Overview: Novanta CEO Matthijs Glastra sold 7,500 common shares on February 10, 2026, for approximately $1.09 million, marking the largest single transaction in his 10 sell-only trades since February 2023, reflecting his liquidity management strategy.
Ownership Changes: Following the sale, Glastra's direct holdings decreased to 57,367 shares, while his indirect holdings via a trust remained unchanged at 54,382 shares, indicating a stable ownership structure without urgency to liquidate his stakes.
Performance Highlights: Novanta reported a 9% year-over-year revenue increase in Q4 2025, reaching $258 million, exceeding expectations and contributing to a 3% annual sales growth to $981 million, with forecasts suggesting sales will surpass $1 billion in 2026, showcasing strong business growth potential.
Market Reaction: While Glastra's stock sale did not raise market concerns, the company's price-to-earnings ratio of 91 indicates a high stock price, suggesting current shareholders consider selling, while potential buyers should wait for a price correction before entering the market.

Novanta CEO Sells 7,500 Shares for $1.09 Million

5 days agoNASDAQ.COM

Executive Sell-off: Novanta CEO Matthijs Glastra sold 7,500 shares on February 10, 2026, for approximately $1.09 million, representing 6.29% of his total holdings, indicating a strategic sell-off at a high stock price.
Stable Holding Structure: Post-transaction, Glastra retains 57,367 shares directly and another 54,382 shares in a trust, suggesting confidence in the company's future and a lack of urgency to liquidate his holdings.
Strong Performance: Novanta reported Q4 revenue of $258 million, a 9% year-over-year increase, and forecasts sales exceeding $1 billion in 2026, highlighting robust growth in high-demand medical and industrial sectors.
Market Reaction Analysis: While Glastra's sale did not raise market concerns, Novanta's price-to-earnings ratio of 91 indicates a high stock price, suggesting investors should consider waiting for a better entry point before purchasing shares.

Novanta Inc. Reports Record Q4 2025 Revenue and Strong Growth

Feb 24 2026seekingalpha

Record Revenue: Novanta Inc. achieved record revenue in Q4 2025 with a reported growth of 9%, including 2% organic growth and 4% sequential growth, reflecting strong performance in the medical technology sector.
Surge in Bookings: The company experienced a 25% year-over-year increase in bookings and a 12% sequential rise, with a book-to-bill ratio of 1.11, indicating double-digit bookings growth across all businesses for the first time since 2022.
Strategic Investments: CEO emphasized strategic investments in minimally invasive surgery, robotic surgery, AI-driven robotics, digital manufacturing, and precision medicine, aiming to enhance the company's leadership in medical technologies and embedded software.
Future Outlook: For 2026, GAAP revenue is projected to be between $1.03 billion and $1.05 billion, representing 4% to 6% organic growth, while adjusted gross margin is expected to expand to 47%, demonstrating the company's confidence in future growth.

Novanta Reports Q4 2025 Earnings with Strong Performance

Feb 24 2026seekingalpha

Earnings Beat: Novanta's Q4 2025 non-GAAP EPS of $0.91 exceeded expectations by $0.08, indicating a robust enhancement in the company's profitability.
Significant Revenue Growth: The quarter's revenue reached $258.3 million, an 8.5% year-over-year increase, surpassing expectations by $4.98 million, reflecting the company's competitive strength and rising customer demand.
Adjusted EBITDA Increase: Adjusted EBITDA rose 17% to $60.7 million compared to $52.1 million last year, demonstrating the company's success in cost control and operational efficiency.
Optimistic Future Outlook: The company expects GAAP revenue for FY 2026 to range between $1.03 billion and $1.05 billion, with adjusted EBITDA projected between $245 million and $250 million, showcasing confidence in future growth despite foreign exchange risks.

Novanta Reports 2025 Financials: Revenue Growth and Profit Improvement

Feb 23 2026Newsfilter

Q4 Performance: In Q4 2025, Novanta achieved GAAP revenue of $258.3 million, a 9% increase year-over-year, with adjusted diluted EPS rising 20% to $0.91, indicating strong performance in the medical technology sector and likely boosting market confidence.
Annual Financial Overview: For the full year 2025, GAAP revenue reached $980.6 million, up 3.3% from the previous year, although organic revenue growth slightly declined by 0.5%, reflecting challenges from intensified market competition despite contributions from acquisitions.
Customer Bookings Growth: The company reported a 14% increase in customer bookings for 2025, with new product revenues exceeding expectations, demonstrating effective responses to technological innovation and market demand, which is expected to lay the groundwork for future revenue growth.
Future Outlook: Novanta anticipates GAAP revenue for 2026 to range between $1.03 billion and $1.05 billion, with adjusted EBITDA projected at $245 million to $250 million, reflecting confidence in ongoing investments and strategic execution aimed at enhancing long-term shareholder value.